HF-158K1 by HighField Biopharmaceuticals for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

Renck: The Sanders brothers look to live up to the hype – The Cannabist

Interviewing Shedeur Sanders and Shilo Sanders together at Wednesday’s Big 12 media day was equal parts informative and comedic. They definitely are brothers, even if

July 11, 2024

Ransomware attack shuts down hospital emergency rooms in several states

You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in

August 8, 2023

Sacklers reach new $7.4 billion settlement over opioid crisis

Purdue Pharma and members of the Sackler family that own the company have agreed to a $7.4 billion settlement in principle with 15 states to

January 23, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.